About Enhancer
| Enhancer ID: | E_01_0434 |
| Species: | human |
| Position : | chr2:15587927-15589927   |
| Biosample name: | |
| Experiment class : | High+Lowthroughput |
| Enhancer type: | Enhancer |
| Disease: | Colorectal neoplasms |
| Pubmed ID: | 29869821 |
| Enhancer experiment: | CRISPR / Cas9,knockdown,Quantitative RT?PCR,Western blot,Luciferase reporter assay,Immunohistochemistry, Immunofluorescence analysis,ChIP |
| Enhancer experiment description: | These results suggest that LGR5 is a critical effector of DDX1 in colorectal cancer cells. The DDX1-LGR5 axis could be a new drug target for this type of malignant cancer. |
About Target gene
| Target gene : | DDX1 |
| Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
| Less strong evidence: | RNA-Seq |
| Target gene experiment description: | These results suggest that LGR5 is a critical effector of DDX1 in colorectal cancer cells. The DDX1-LGR5 axis could be a new drug target for this type of malignant cancer.;These results suggest that LGR5 is a critical effector of DDX1 in colorectal cancer cells. The DDX1-LGR5 axis could be a new drug target for this type of malignant cancer.;These results suggest that LGR5 is a critical effector of DDX1 in colorectal cancer cells. The DDX1-LGR5 axis could be a new drug target for this type of malignant cancer. |
About TF
| TF name : | LGR5SOX2(ANOP3,MCOPS3) |
| TF experiment: | CRISPR / Cas9,knockdown,Quantitative RT?PCR,Western blot,Luciferase reporter assay,Immunohistochemistry, Immunofluorescence analysis,ChIP |
| TF experiment description: | These results suggest that LGR5 is a critical effector of DDX1 in colorectal cancer cells. The DDX1-LGR5 axis could be a new drug target for this type of malignant cancer.;These results suggest that LGR5 is a critical effector of DDX1 in colorectal cancer cells. The DDX1-LGR5 axis could be a new drug target for this type of malignant cancer.;These results suggest that LGR5 is a critical effector of DDX1 in colorectal cancer cells. The DDX1-LGR5 axis could be a new drug target for this type of malignant cancer. |
About Function
| Enhancer function : | These results suggest that LGR5 is a critical effector of DDX1 in colorectal cancer cells. The DDX1-LGR5 axis could be a new drug target for this type of malignant cancer. |
| Enhancer function experiment: | Immunohistochemical staining |
| Enhancer function experiment description: |
These results suggest that LGR5 is a critical effector of DDX1 in colorectal cancer cells. The DDX1-LGR5 axis could be a new drug target for this type of malignant cancer. |
About SNP
| SNP ID: | -- |
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| LGR5 | Regulation of FZD by ubiquitination | reactome | 21 |
| SOX2 | Deactivation of the beta-catenin transactivating complex | reactome | 42 |
| SOX2 | POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | reactome | 13 |
| SOX2 | POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | reactome | 10 |
| SOX2 | Transcriptional regulation of pluripotent stem cells | reactome | 28 |
| SOX2 | Hs_Endoderm_Differentiation_WP2853_88152 | wikipathways | 62 |
| SOX2 | Hs_Dopaminergic_Neurogenesis_WP2855_87239 | wikipathways | 19 |
| SOX2 | Hs_Wnt_Signaling_Pathway_and_Pluripotency_WP399_90291 | wikipathways | 12 |
| SOX2 | Hs_Mesodermal_Commitment_Pathway_WP2857_87780 | wikipathways | 47 |
| SOX2 | Hs_Ectoderm_Differentiation_WP2858_89329 | wikipathways | 56 |
Enhancer associated network
The number on yellow line represents the distance between enhancer and
target gene